About NeoCura

Technical superiority

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

Pipelines leadership

More than 10 First-in-Class R&D pipelines focusing on mRNA tumor neoantigen vaccines , tumor microenvironment immuno-modulator, and virus vaccines

Team advantages

A top-notch complementarity team, bringing together top experts from tumor immunology, RNA delivery, molecular engineering, artificial intelligence, and industrialization fields



Resource integration

Gather strength by integrating top resources in research, industry, and clinical fields at home and abroad to break through obstacles

AI empowerment

AI empowers RNA throughout the entire flow process, accelerating research and development of drugs and technology upgrades







Development history


2021


December

RMB 500 million A+ round financing was completed

December

Strategic cooperation was reached with Integrated Nanotherapeutics

November

IIT trial for mRNA tumor neoantigen vaccine was initiated at Peking University Cancer Hospital

October

Strategic cooperation was reached with Innovent and MDimune

September

IIT trial for mRNA tumor neoantigen vaccine was initiated at Chinese PLA General Hospital (301 Hospital)

June

Beijing R&D center was put into use



2023


March

XH101 injection IND application was accepted by CDE

March

Strategic partnership was established with Gene+

February

IIT trial for the second mRNA tumor neoantigen vaccine was initiated at Chinese PLA General Hospital (301 Hospital)


2022


September

NeoCura (Beijing) was approved for municipal-level "Key Technology Innovation for Science and Technology-type Small and Micro Enterprises" policy support

July

IIT trial for mRNA tumor neoantigen vaccine was initiated at Peking Union Medical College Hospital in Beijing

January

Guangzhou GMP production center was put into use

January

R&D cooperation was reached with PhoreMost

2020



December

RMB 250 million A round financing was completed

August

NeoCura (Shenzhen) laboratory passed the NCCL quality evaluation with a full score

May

IIT trial for mRNA tumor neoantigen vaccine was initiated at the First Affiliated Hospital of Zhengzhou University

2020


2019


July

Shenzhen R&D center was officially put into use

2023

Scan code to follow us on WeChat

NeoCura Bio-Medical Technology Co., Ltd.

Beijing: Room C301, No. 29 Shengmingyuan Road, Life Science Park, Changping District, Beijing





Websitewww.neocura.com.cn

E-mailinfo@neocura.net

             bd@neocura.net

             pr@neocura.net

Tel+86 10 80766127




Guangzhou: 10/F, Block B, No. 388 Lianyun Road, Huangpu District, Guangzhou, China





Shenzhen: 12/F, Block B, Building 1, Yinxingzhijie Phase II, Longhua District, Shenzhen, China

Address:

  • Telephone

    • 010-80766127
  • ΢ɨһɨ

ض seo seo